PPD increases stake in small molecule discovery company X-Chem citing Big Pharma relationships

By Zachary Brennan contact

- Last updated on GMT

PPD increases stake in small molecule discovery company X-Chem

Related tags: Pharmacology

CRO PPD has exercised its option to acquire the remaining minority ownership interest of X-Chem for an undisclosed sum. X-Chem will continue to operate as a small molecule discovery company with its entire existing staff and management team. 

Back in October 2010, PPD acquired a controlling interest in X-Chem, along with the right to purchase the remaining interest on or before October 31, 2014.

PPD says that its decision to acquire the remaining minority interest in X-Chem is based on “the successful business model that X-Chem has built and the growing interest by pharmaceutical firms to gain access to X-Chem’s proprietary small molecule discovery technology​.”

Four years ago, PPD made a strategic decision to invest in X-Chem, based on their highly innovative drug discovery engine​,” David Simmons, chairman and CEO of PPD said.

X-Chem has demonstrated the value of its technology through establishment of an increasing number of relationships with major pharmaceutical and biotechnology companies, along with academic centers. Through these relationships, X-Chem has emerged as one of the top small molecule drug discovery companies in the biotechnology industry.​”

X-Chem has established partnerships with Roche, AstraZeneca, Bayer, Pfizer, and two other unnamed major pharma companies since 2010, as well as several biotechnology companies and top tier academic institutions.

In its work with partners, the company uses a proprietary DNA-encoded small molecule library with more than 100bn distinct compounds to help generate novel drugs against dozens of validated targets.

CEO and founder of X-Chem Richard Wagner added: “We have enjoyed a highly productive and collaborative relationship with PPD to date and share a belief in the potential of X-Chem to transform drug discovery through broad application of our technology to a wide spectrum of targets and therapeutic areas. We look forward to additional success for our two companies and the patient communities we ultimately aspire to help​.”

Related news

Show more

Related products

show more

How clinical trial software can optimize trials

How clinical trial software can optimize trials

Formedix | 20-Jun-2022 | Technical / White Paper

This article explains the different types of clinical trial software available, and how it can be used to optimize the end to end clinical trials design...

Flexible Filling Solution for CMOs

Flexible Filling Solution for CMOs

Single Use Support GmBH | 18-May-2022 | Insight Guide

Achieving flexibility requires modularity of technologies.

CMOs and CDMOs aspire to be flexible for multiple applications. Efficient automated...

Governing and Maintaining Clinical Data Standards

Governing and Maintaining Clinical Data Standards

Veeva | 10-May-2022 | Technical / White Paper

Investing in data standards plays a huge role in improving the quality of clinical studies. But often, people don’t use the standards correctly, there...

What the Best Clinical Study Build Pros Do

What the Best Clinical Study Build Pros Do

Formedix | 09-May-2022 | Technical / White Paper

Getting your clinical study designed and built ready for data collection takes A LOT of work and expertise… you've got to do all your CRF designs;...

Related suppliers

Follow us

Products

View more

Webinars